Results 101 to 110 of about 3,339,972 (325)
Functional dyspepsia involves duodenal barrier dysfunction, low‐grade immune activation and altered neuroimmune signalling. Various plant‐derived bioactives may modulate PPAR signalling, reduce inflammatory and oxidative stress, and support epithelial, immune, metabolic, and sensory homeostasis.
Irene Palenca +5 more
wiley +1 more source
Cannabinoids and alcohol co-exposure modulate pathogen-induced pulmonary immune responses
Both alcohol and cannabinoid misuse cause substantial societal problems individually, and cannabis is the most popular illicit drug used simultaneously with alcohol.
De’Jana Parker, Vijay Sivaraman
doaj +1 more source
The Endocannabinoid System in the Retina: From Physiology to Practical and Therapeutic Applications
Cannabis is one of the most prevalent drugs used in industrialized countries. The main effects of Cannabis are mediated by two major exogenous cannabinoids: ∆9-tetrahydroxycannabinol and cannabidiol.
Thomas Schwitzer +4 more
doaj +1 more source
ABSTRACT N‐acylethanolamines (NAEs) are endogenous fatty acid amides structurally related to the endocannabinoid anandamide and function as bioactive lipid mediators with broad regulatory roles in inflammation and neuroinflammation. Among pattern‐recognition receptors, Toll‐like receptor 4 (TLR4) occupies a central position in innate immune ...
Damiana Scuteri +5 more
wiley +1 more source
Long-term activation of polymorph cannabinoid receptors does not affect receptor gene transcription.
Long-term activation of polymorph cannabinoid receptors does not affect receptor gene ...
L. Beishon (7688777) +3 more
core +5 more sources
Cannabinoids have been used to treat pain for many centuries. However, only during the past several decades have rigorous scientific methods been applied to understand the mechanisms of cannabinoid action.
J Michael Walker +2 more
doaj +1 more source
Abstract Background and aims Currently, there is no data‐driven cannabis reduction metric using biochemical verification, which represents a significant gap in cannabis harm reduction research, treatment and policy. Using aggregated data from 7 cannabis use disorder treatment trials, the aims of this analysis were to 1) determine if decreases in self ...
Erin A. McClure +6 more
wiley +1 more source
Varenicline for cannabis use disorder: A randomized controlled trial
Abstract Background and aims Although cannabis use is widespread and prevalence of cannabis use disorder (CUD) is increasing, limited advancements have been made in CUD medication development. The objective of this study was to test the efficacy of varenicline with medical management for reducing cannabis use in treatment‐seeking individuals with CUD ...
Aimee L. McRae‐Clark +8 more
wiley +1 more source
CNS effects of CB2 cannabinoid receptors: beyond neuro-immuno-cannabinoid activity
There are two well characterized cannabinoid receptors (CBRs), CB1-Rs and CB2-Rs, with other candidates, such as GPR55, PPARs and vanilloid TRPV1 (VR1) receptors, which are either activated by cannabinoids and/or endocannabinoids (eCBs). The neuronal and
E. Onaivi +3 more
semanticscholar +1 more source
Abstract Background and aims Cannabis is the most widely used illicit drug worldwide and is often co‐used with tobacco, the leading cause of preventable death. Although cannabis and tobacco have distinct neurobiological actions, their associations with brain volumes are unclear.
Katherine Sawyer +16 more
wiley +1 more source

